Simvastatin-mediated enhancement of long-term potentiation is driven by farnesyl-pyrophosphate depletion and inhibition of farnesylation

Neuroscience

Volumn 202, Issue , 2012, Pages 1-9

  Mans, R A ^a,b   McMahon, L L ^a,c   Li, L ^a,b,d  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Hippocampus; Isoprenoids; Long term potentiation; Protein prenylation; Statins; Synaptic plasticity

Indexed keywords

FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; ISOPRENOID; MEVALONIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN FARNESYLTRANSFERASE; PROTEIN KINASE B; SIMVASTATIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEPLETION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; HIPPOCAMPAL CA1 REGION; LONG TERM POTENTIATION; MALE; MENTAL FUNCTION; MOUSE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WILD TYPE;

ALKYL AND ARYL TRANSFERASES; ANIMALS; BLOTTING, WESTERN; CA1 REGION, HIPPOCAMPAL; DITERPENES; ELECTROPHYSIOLOGICAL PHENOMENA; FARNESOL; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LONG-TERM POTENTIATION; MALE; MEVALONIC ACID; MICE; MICE, INBRED C57BL; PHOSPHATIDYLINOSITOL 3-KINASES; POLYISOPRENYL PHOSPHATES; PRENYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SESQUITERPENES; SIGNAL TRANSDUCTION; SIMVASTATIN;

EID: 84856228305     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.12.007     Document Type: Article

References (33)

1. Bösel J., Gandor F., Harms C., Synowitz M., Harms U., Djoufack P.C., Megow D., Dirnagl U., Hörtnagl H., Fink K.B., Endres M. Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. J Neurochem 2005, 92:1386-1398.
2. Chen J., Zhang Z.G., Li Y., Wang Y., Wang L., Jiang H., Zhang C., Lu M., Katakowski M., Feldkamp C.S., Chopp M. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003, 53:743-751.
3. Clarke R.M., Lyons A., O'Connell F., Deighan B.F., Barry C.E., Anyakoha N.G., Nicolaou A., Lynch M.A. A pivotal role for interleukin-4 in atorvastatin-associated neuroprotection in rat brain. J Biol Chem 2008, 283:1808-1817.
4. Cole S.L., Vassar R. Isoprenoids and Alzheimer's disease: a complex relationship. Neurobiol Dis 2006, 22:209-222.
5. Collins R., Armitage J., Parish S., Sleight P., Peto R. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
6. Cordle A., Landreth G. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses. J Neurosci 2005, 25:299-307.
7. Crick D.C., Andres D.A., Waechter C.J. Novel salvage pathway utilizing farnesol and geranylgeraniol for protein isoprenylation. Biochem Biophys Res Commun 1997, 237:483-487.
8. Dai C., Whitesell L., Rogers A.B., Lindquist S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 2007, 130:1005-1018.
9. Douma T.N., Borre Y., Hendriksen H., Olivier B., Oosting R.S. Simvastatin improves learning and memory in control but not in olfactory bulbectomized rats. Psychopharmacology (Berl) 2011, 216:537-544.
10. Eckert G.P., Hooff G.P., Strandjord D.M., Igbavboa U., Volmer D.A., Müller W.E., Wood W.G. Regulation of the brain isoprenoids farnesyl- and geranylgeranylpyrophosphate is altered in male Alzheimer patients. Neurobiol Dis 2009, 35:251-257.
11. Endo A. The discovery and development of HMG-CoA reductase inhibitors. Atheroscler Suppl 2004, 5:67-80. 1992.
12. Essig M., Vrtovsnik F., Nguyen G., Sraer J.D., Friedlander G. Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells: role of geranylgeranylation and Rho proteins. J Am Soc Nephrol 1998, 9:1377-1388.
13. Fritz G. Targeting the mevalonate pathway for improved anticancer therapy. Curr Cancer Drug Targets 2009, 9:626-638.
14. Jick H., Zornberg G.L., Jick S.S., Seshadri S., Drachman D.A. Statins and the risk of dementia. Lancet 2000, 356:1627-1631.
15. Jones P.H. Comparing HMG-CoA reductase inhibitors. Clin Cardiol 2003, 26:I15-I20.
16. Kuenzi F.M., Fitzjohn S.M., Morton R.A., Collingridge G.L., Seabrook G.R. Reduced long-term potentiation in hippocampal slices prepared using sucrose-based artificial cerebrospinal fluid. J Neurosci Methods 2000, 100:117-122.
17. Li L., Cao D., Kim H., Lester R., Fukuchi K. Simvastatin enhances learning and memory independent of amyloid load in mice. Ann Neurol 2006, 60:729-739.
18. Li W., Cui Y., Kushner S.A., Brown R.A., Jentsch J.D., Frankland P.W., Cannon T.D., Silva A.J. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol 2005, 15:1961-1967.
19. Manabe T., Aiba A., Yamada A., Ichise T., Sakagami H., Kondo H., Katsuki M. Regulation of long-term potentiation by H-Ras through NMDA receptor phosphorylation. J Neurosci 2000, 20:2504-2511.
20. Mans R.A., Chowdhury N., Cao D., McMahon L.L., Li L. Simvastatin enhances hippocampal long-term potentiation in C57BL/6 mice. Neuroscience 2010, 166:435-444.
21. McTaggart S.J. Isoprenylated proteins. Cell Mol Life Sci 2006, 63:255-267.
22. Opazo P., Watabe A.M., Grant S.G., O'Dell T.J. Phosphatidylinositol 3-kinase regulates the induction of long-term potentiation through extracellular signal-related kinase-independent mechanisms. J Neurosci 2003, 23:3679-3688.
23. Racaniello M., Cardinale A., Mollinari C., D'Antuono M., De Chiara G., Tancredi V., Merlo D. Phosphorylation changes of CaMKII, ERK1/2, PKB/Akt kinases and CREB activation during early long-term potentiation at Schaffer collateral-CA1 mouse hippocampal synapses. Neurochem Res 2010, 35:239-246.
24. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., Ford I., Gaw A., Hyland M., Jukema J.W., Kamper A.M., Macfarlane P.W., Meinders A.E., Norrie J., Packard C.J., Perry I.J., Stott D.J., Sweeney B.J., Twomey C., Westendorp R.G. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360:1623-1630.
25. Thornton C., Yaka R., Dinh S., Ron D. H-Ras modulates N-methyl-d-aspartate receptor function via inhibition of Src tyrosine kinase activity. J Biol Chem 2003, 278:23823-23829.
26. van der Heide L.P., Kamal A., Artola A., Gispen W.H., Ramakers G.M. Insulin modulates hippocampal activity-dependent synaptic plasticity in a N-methyl-d-aspartate receptor and phosphatidyl-inositol-3-kinase-dependent manner. J Neurochem 2005, 94:1158-1166.
27. Wagner A.H., Köhler T., Rückschloss U., Just I., Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000, 20:61-69.
28. Wagstaff L.R., Mitton M.W., Arvik B.M., Doraiswamy P.M. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003, 23:871-880.
29. Wang Q., Zengin A., Deng C., Li Y., Newell K.A., Yang G.Y., Lu Y., Wilder-Smith E.P., Zhao H., Huang X.F. High dose of simvastatin induces hyperlocomotive and anxiolytic-like activities: the association with the up-regulation of NMDA receptor binding in the rat brain. Exp Neurol 2009, 216:132-138.
30. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000, 57:1439-1443.
31. Wu H., Lu D., Jiang H., Xiong Y., Qu C., Li B., Mahmood A., Zhou D., Chopp M. Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K/Akt pathway, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury. J Neurotrauma 2008, 25:130-139.
32. Yaka R., Thornton C., Vagts A.J., Phamluong K., Bonci A., Ron D. NMDA receptor function is regulated by the inhibitory scaffolding protein, RACK1. Proc Natl Acad Sci U S A 2002, 99:5710-5715.
33. Zacco A., Togo J., Spence K., Ellis A., Lloyd D., Furlong S., Piser T. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci 2003, 23:11104-11111.